Head-to-head · Value Score
CoreAge Rx vs SkyRx
Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 93, SkyRx a 63. Here's who gives you the honest lower price — and where each one bites back.
CoreAge Rx
#1 · Grade A+ · Best Value
Est. first month
$99/mo
Save ~89% vs brand-nameSkyRx
#350 · Grade C · Watch List
Est. first month
From $199/mo (all doses, 12-month plan, compounded)
Save ~85% vs brand-nameThe verdict
CoreAge Rx takes it on Value Score, 93 to 63 — an est. $99/mo first month, with no teaser step-up baked in. SkyRx isn't out of it: Someone committed to semaglutide for a year who wants a 503B pharmacy behind it.
CoreAge Rx is also our overall #1 pick across the whole deals ranking — a flat, all-in price on both molecules in all 50 states. That's why it wins here on the score, not just this matchup.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | CoreAge Rx | SkyRx |
|---|---|---|
| Value Score | 93 (A+) | 63 (C) |
| Est. first month | $99/mo | From $199/mo (all doses, 12-month plan, compounded) |
| Save vs brand-name | ~89% | ~85% |
| Semaglutide | $99/mo | From $199/mo (all doses, 12-month plan, compounded) |
| Tirzepatide | $149/mo | Not disclosed |
| Both molecules | Yes | No |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | Coverage not published |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
CoreAge Rx
The honest lowest price: both molecules at one flat, all-in monthly rate that never steps up after month one.
Why it's a deal
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation — no lock-in
The fine print
- Not the rock-bottom sticker — a couple of teaser tiers advertise lower month-one rates
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
SkyRx
SkyRx sells compounded semaglutide as either an injection or oral drops from $199 a month on a twelve-month prepaid plan, dispensed through FDA-registered 503B pharmacies, with tirzepatide still listed as coming soon.
Why it's a deal
- Dispenses through US-based 503B compounding pharmacies registered with the FDA — the more heavily regulated of the two routes, and stated explicitly
- Maintains LegitScript certification
- Oral drops are priced the same as the injection at $199, so the needle-free route carries no premium
- Says outright that GLP-1s are not available in every state rather than implying nationwide coverage
The fine print
- The $199 rate requires a twelve-month subscription paid up front — there is no month-to-month figure published beside it
- Tirzepatide is listed as coming soon in both injection and oral form, so semaglutide is the only real choice today
- The states it does serve are never enumerated, so eligibility is unknown until you apply
- Compounded only — no FDA-approved brand-name route
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores CoreAge Rx is ranked on the CoreAge Rx alternatives ranking, and the same list for the other side is on alternatives to SkyRx.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.